Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-17
2007-04-17
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S141000, C546S142000
Reexamination Certificate
active
10950802
ABSTRACT:
The present invention is directed to a compound of formula (I), or a stereoisomer or a mixture of stereoisomer thereof in any ratio, or its physiologically tolerable salt, which is useful as an inhibitor of matrix metalloproteinase. The present invention is also directed to a pharmaceutical preparation comprising a pharmaceutically effective amount of at least one compound of formula (I); processes for their preparation; the use of a compound of formula (I) having activity as an matrix metalloproteinase inhibitor; and for the prophylaxis and therapy of disease states that involve an increase in the activity of matrix metalloproteinase.
REFERENCES:
patent: 4691022 (1987-09-01), Henning et al.
patent: 4902695 (1990-02-01), Ornstein et al.
patent: 5430023 (1995-07-01), Gesellchen et al.
patent: 5726159 (1998-03-01), Aaron et al.
patent: 5990145 (1999-11-01), Wehner et al.
patent: 6207672 (2001-03-01), Thorwart
patent: 6376506 (2002-04-01), Brokàet al.
patent: 6573277 (2003-06-01), Thorwart
patent: 0643073 (1995-03-01), None
patent: 0672665 (1995-09-01), None
patent: WO 94/28889 (1994-12-01), None
patent: WO 03/041641 (2003-05-01), None
2002:312012 HCAPLUS.
Fisher et al., “Recent Advances in MMP Inhibitor Design,” Cancer Metastasis Review, vol. 25, pp. 115-136 (2006).
Broka et al., STN International (2006), HCPLUS Database, Accession No.: 2002:312012., RN 210915-36-9.
U.S. Appl. No. 10/376,287, filed Nov. 4, 1996, Thorwart.
Alcaide, et al., The Intramolecular Aldol Condensation Route to Fused Bi- and Tricyclic-B-Lactams1,2, J. Org. Chem. (1996) vol. 61 7125-7132.
Bergmeier, et al., Synthesis of Bicyclic Proline Analogs Using a Formal [3 +2] Intramolecular Aziridine-Allysilane Cycloaddition Reaction, Tetrahedron vol. 55 (1999) pp. 8025-8038.
Creemers, E.J.M., et al., Matrix Metalloproteinase Inhibition after Myocardial Infarction A New Approach to Prevent Heart Failure?, Circulation Res. vol. 89, (2001) pp. 201-210.
Esch, et al., Reductive Cyclization of Carbon-Centered Glycine Radicals; A Novel Synthetic route to Cyclic a-Amino Acids, Tetrahedron vol. 48, No. 22, (1992) pp. 4659-4676.
George, S. et al., Therapeutic Potential of Matrix Metalloproteinase Inhibitors in Atherosclerosis, Expert Opinion on Investigational Drugs (2000) vol. 9 No. 5, pp. 993-1007.
Henning, et al., Diastereoselective Synthesis of Bicyclic Amino Acids Via Ring Contraction of a-Chlorolactams, Tetrahedron Letters, vol. 24, No. 48, (1983) pp. 5339-5342.
Li, et al., Matrix Metalloproteinases in the Progression of Heart Failure Potential Therapeutic Implications, Drugs vol. 61 No. 9 (2001) pp. 1239-1252.
Massova Irina et al., Matrix Metalloproteinases: Structures, Evolution, and Diversification, The FASEB Journal, 1998, vol. 12, pp. 1075-1095.
Michaelides Michael R et al., Recent Advances in Matrix Metalloproteinases Inhibitors Research, Current Pharmaceutical Design, 1999, vol. 5, pp. 787-819.
Skiles, et al., The Design, Structure, and Therapeutic Application of Matrix Metalloproteinase Inhibitors, Current Medicinal Chemistry vol. 8 (2001) pp. 425-474.
Tverezovsky, et al., Synthesis of (2S,3R,4S)-3.4-Methanoproline and Analogues by Cyclopropylidene Insertion, Tetrahedron vol. 53, No. 43 (1997) pp. 14773-14792.
Ye Qi-Zhuang et al., Purification and Characterization of the Human Stromelysin Catalytic Domain Expressed inEscherichia coli, Biochemistry, 1992, vol. 31, pp. 11231-11235.
Yip, Desmond et al., Matrix Metalloproteinase Inhibitors: Applications in Oncology, Investigational New Drugs, 1999, vol. 17, pp. 387-399.
Hofmeister Armin
Matter Hans
Schudok Manfred
Freistein Andrew B.
Ort Ronald G.
Saeed Kamal A.
Sanofi-Aventis Deutschland GmbH
LandOfFree
Bicyclic imino acid derivatives as inhibitors of matrix... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic imino acid derivatives as inhibitors of matrix..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic imino acid derivatives as inhibitors of matrix... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3732912